Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Balloon-based endoscopic ablation can eliminate Barrett's

Circumferential ablation of Barrett's using balloon-based endoscopic radiofrequency eliminates the disease in the majority of patients, shows February's Gastrointestinal Endoscopy.

News image

fiogf49gjkf04

Dr Virender Sharma and colleagues from Arizona assessed the dose-response, safety, and efficacy of circumferential endoscopic ablation of Barrett's esophagus.

The researchers used an endoscopic balloon-based ablation device that delivered a pre-set amount of energy density to Barrett's tissue.

The researchers conducted the study in 2 serial phases at 8 centers between 2003 and 2005.

The first phase included the dosimetry phase, which evaluated the dose-response and the safety of delivering 6 to 12 J/cm2 in 32 patients.

The second was the effectiveness phase, and used 10 J/cm2 in 70 patients.

There was a complete response for Barrett's in 70% of patients
Gastrointestinal Endoscopy

The procedures were delivered twice for all patients, followed by EGD with biopsies at 1, 3, 6, and 12 months.

The researcher performed a second ablation procedure if Barrett' esophagus was present at 1 or 3 months.

Patients received esomeprazole 40 mg twice a day for 1 month after ablation, and 40 mg every day thereafter.

The team quantified postablation symptoms by using a 14-day symptom diary.

The researchers defined a complete response as all biopsy specimens negative for Barrett's esophagus at 12 months.

Patients were 18 to 75 years of age, with a diagnosis of Barrett's esophagus and without dysplasia.

The patients had histopathology reconfirmation of the diagnosis within 6 months of enrollment.

Median symptom scores returned to a score of 0 of 100 by day 3 in the dosimetry phase.

The team observed no dose-related serious adverse events.

The outcomes at 1 and 3 months permitted the selection of 10 J/cm2 for the subsequent effectiveness phase of the study.

During the effectiveness phase, the team noted that median symptom scores returned to a score of 0 of 100 by day 4.

At 12 months, the researchers achieved a complete response for Barrett's esophagus in 70% of patients.

The researchers found no strictures, and no buried glandular mucosa in either study phase.

Dr Sharma's team concludes, “Circumferential ablation of nondysplastic Barrett's esophagus by using this balloon-based ablation device can be performed with no subsequent strictures or buried glands.

“This method completely eliminates Barrett's esophagus in 70% of patients at 1-year follow-up.”

Gastrointest Endoscopy 2007: 65(2): 185-95
07 February 2007

Go to top of page Email this page Email this page to a colleague

 24 May 2018 
Precision medicine for tumors
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 23 May 2018 
High body mass index is and ulcerative colitis
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Fecal incontinence and quality of life in IBD
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Esophageal dilatation in clinical practice 
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us